Latest Safety News

Page 59 of 205
Karoon Energy delivered 2025 production near the upper guidance range, marked by a leadership change and significant operational improvements. The company outlines cautious yet optimistic 2026 growth and cost guidance amid ongoing maintenance and exploration activities.
Maxwell Dee
Maxwell Dee
27 Jan 2026
Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.
Ada Torres
Ada Torres
27 Jan 2026
PC Gold Ltd has secured approvals to re-open the historical Spring Hill underground adit, enabling cost-effective underground drilling to assess high-grade gold mineralisation and potentially expand its resource base.
Maxwell Dee
Maxwell Dee
27 Jan 2026
Ioneer Ltd has reported a significant uplift in the economics of its Rhyolite Ridge lithium-boron project, alongside ongoing strategic partnership talks and strong market demand for lithium and boric acid.
Maxwell Dee
Maxwell Dee
23 Jan 2026
Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.
Victor Sage
Victor Sage
23 Jan 2026
Life360 has reported its strongest quarter ever, with record user and subscriber growth in Q4 2025, surpassing full-year revenue and EBITDA guidance. The company forecasts continued momentum with 20% user growth expected in 2026.
Sophie Babbage
Sophie Babbage
23 Jan 2026
Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.
Ada Torres
Ada Torres
23 Jan 2026
Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.
Ada Torres
Ada Torres
23 Jan 2026
Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.
Ada Torres
Ada Torres
23 Jan 2026
Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.
Ada Torres
Ada Torres
23 Jan 2026
PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.
Ada Torres
Ada Torres
23 Jan 2026
Structural Monitoring Systems Plc reports a profitable December quarter with 40% revenue growth, driven by strong avionics sales and progress toward FAA certification of its CVM™ technology.
Sophie Babbage
Sophie Babbage
23 Jan 2026